✓ Medically reviewed by · Last reviewed: May 2026
Pharmacy Researcher · 8 years experience
Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.
Key takeaways
- AHK-Cu is a hair-follicle-selective copper tripeptide. Single N-terminal residue substitution (alanine for glycine) on GHK shifts activity toward dermal-papilla effects.
- Mechanism: dermal-papilla cell activation with measurable hair-shaft thickening and anagen-phase prolongation in in-vitro follicle-culture models.
- Requires copper chelation for the published activity. The free peptide is largely inactive at the relevant endpoints.
- Most-published as the hair-specific complement to GHK-Cu in combined hair-loss research protocols.
- This guide covers the hair-selective mechanism, dosing, and where AHK-Cu fits in cosmetic and hair-loss research.
AHK-Cu Peptide: Hair-Follicle-Selective Copper Tripeptide Research Guide
AHK-Cu is the hair-specific variant of the copper-chelated tripeptide research compound. The molecule shares the core architecture of GHK-Cu — a tripeptide bound to a Cu(II) ion — but a single N-terminal residue substitution shifts the activity profile toward hair-follicle-selective effects. For research-protocol design where dermal-papilla activation is the endpoint, AHK-Cu is the more concentrated mechanism option.
What is AHK-Cu
AHK is alanyl-L-histidyl-L-lysine — a tripeptide identical to GHK except for the N-terminal glycine replaced by alanine. In its copper-chelated form (AHK-Cu), the molecule binds dermal-papilla cells with substantially higher activity than the GHK-Cu variant. The Cu(II) chelate is required for the published research activity; the free peptide is measurably active but at substantially smaller effect sizes.
Mechanism
AHK-Cu acts at the dermal papilla — the signalling hub at the base of the hair follicle responsible for regulating the hair-growth cycle. Published in-vitro research shows AHK-Cu activates dermal-papilla cells more efficiently than GHK-Cu at matched concentrations, with measurable effects on:
- Hair-shaft thickening — increased mean shaft diameter in cultured follicle models
- Anagen-phase prolongation — longer active-growth phase in follicle-cycle research
- Dermal-papilla cell proliferation — the cellular basis for follicle revitalisation
The single-residue substitution (alanine for glycine) affects the copper-chelate geometry and surface charge profile of the molecule, shifting the activity toward follicle-specific endpoints while attenuating the broader-mechanism effects (collagen synthesis, wound healing) that GHK-Cu dominates.
Research applications
Hair-loss research is the dominant application. Published research uses AHK-Cu in: androgenetic alopecia research models; chemotherapy-induced alopecia research; scalp-condition research with hair-loss endpoints; combined-mechanism hair-loss research alongside small-molecule comparators (finasteride for DHT-axis, minoxidil for vascular); and cosmetic-formulation research in topical hair-care products.
Research dosing
Topical formulations typically use 0.005% – 0.05% (50 ppm to 500 ppm) AHK-Cu concentrations in research-formulation work. Subcutaneous administration is less common but published for systemic-follicle research scenarios. Topical is the dominant route reflecting the cosmetic-formulation-research origin of most published AHK-Cu work.
Side-effect profile
Favourable in published research at the working concentrations used in cosmetic and hair-research protocols. Copper-mediated oxidation of adjacent residues is not a documented concern at the working concentrations. No documented systemic adverse effects from topical AHK-Cu use in published research.
Comparator and stacking
The closest mechanistic comparator is GHK-Cu — see GHK-Cu vs AHK-Cu for the side-by-side comparison. The published hair-loss research protocol typically pairs AHK-Cu with GHK-Cu rather than treating them as competing options: GHK-Cu provides the broader scalp-tissue mechanism, AHK-Cu provides the follicle-selective amplifier. See: GHK-Cu for hair-loss research guide and Best cosmetic peptides.
Storage and reconstitution
Lyophilized vials at -20 °C long-term, 2-8 °C working stock. For topical-formulation work, reconstitute in the appropriate formulation vehicle. For SC research, reconstitute with bacteriostatic water; reconstituted solution at 2-8 °C with use within ~30 days; protect from light; never freeze-thaw.
Safety and regulatory status
AHK-Cu has no FDA / EMA / MHRA approval. The research-grade compound is sold for in-vitro laboratory research and analytical reference use only. None of this constitutes medical advice for hair-loss applications.
FAQ
How is AHK-Cu different from GHK-Cu?
Single-residue substitution (alanine for glycine at the N-terminus). The substitution preserves copper-chelate binding but shifts the activity profile toward hair-follicle-selective effects. AHK-Cu activates dermal-papilla cells more efficiently than GHK-Cu; GHK-Cu has broader applicability across collagen, matrix, wound healing, and partial follicle activity.
Is AHK-Cu “stronger” than GHK-Cu?
Only at the dermal-papilla / hair-follicle endpoint specifically. AHK-Cu is more concentrated activity at the follicle; GHK-Cu is more effective at collagen / matrix / wound-healing endpoints. The molecules have different endpoint specificity, not different overall potency.
Can both be combined in hair-loss research?
Yes — this is the published combination protocol. GHK-Cu addresses multiple skin and scalp-tissue pathways at once (matrix remodelling, anti-inflammatory effects, vascular effects on follicle blood supply); AHK-Cu provides more concentrated activity at the dermal papilla specifically. The combination covers the local follicle endpoint plus the broader scalp-tissue environment.
Does AHK-Cu need to be paired with finasteride or minoxidil?
The mechanisms are non-overlapping. Finasteride works through 5α-reductase inhibition (DHT axis). Minoxidil works through potassium-channel-opener vasodilation. AHK-Cu works through dermal-papilla activation. Combined research protocols use peptides as an additional mechanism arm rather than direct comparators.
What’s the typical research concentration?
Topical formulations: 0.005% – 0.05% (50-500 ppm). Subcutaneous: less common but published for systemic-follicle research at standard SC dose ranges.
Storage protocol?
Lyophilized at -20 °C long-term, 2-8 °C working; reconstituted at 2-8 °C use within 30 days; protect from light; never freeze-thaw.
Bottom line
AHK-Cu is the hair-follicle-selective copper-chelate tripeptide complementing GHK-Cu’s broader cosmetic-research applicability. The single N-terminal residue substitution (alanine for glycine) shifts the activity profile toward dermal-papilla-selective effects, making AHK-Cu the more concentrated mechanism for hair-loss research specifically. Most-paired with GHK-Cu rather than substituted for it — the two molecules cover complementary endpoints in combined hair-loss research protocols.
Related research guides
Written by
Sophie ChenPharmaceutical Content Researcher · 8 years experience
Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.